scispace - formally typeset
M

Martin Mueller-Zsigmondy

Researcher at Novartis

Publications -  12
Citations -  578

Martin Mueller-Zsigmondy is an academic researcher from Novartis. The author has contributed to research in topics: Pharmacokinetics & Dissolution testing. The author has an hindex of 5, co-authored 10 publications receiving 464 citations.

Papers
More filters
Journal ArticleDOI

Setting accelerated dissolution test for PLGA microspheres containing peptide, investigation of critical parameters affecting drug release rate and mechanism

TL;DR: Flow-through method was confirmed as the most appropriate for accelerated in vitro dissolution testing for a given formulation for peptide loaded PLGA microspheres using flow-through apparatus and assessment of the effect of dissolution parameters on drug release rate and mechanism.
Journal ArticleDOI

Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations.

TL;DR: Lack of restrictions on ribociclib dosing may facilitate better patient compliance and therefore clinical benefit, and no impact of gastric pH‐altering agents on the absorption of ribocIClib is stated, without a dedicated drug–drug interaction trial.
Journal ArticleDOI

Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies.

TL;DR: In this paper, the authors report five case studies on using PBBM to establish a safe space for BCS Class 2 and 4 across different companies, including applications in an industrial setting for both internal decision making or regulatory applications.